Literature DB >> 17685811

The effect of sildenafil citrate (Viagra) on visual sensitivity.

Andrew Stockman1, Lindsay T Sharpe, Adnan Tufail, Philip D Kell, Caterina Ripamonti, Glen Jeffery.   

Abstract

The erectile dysfunction medicine sildenafil citrate (Viagra) inhibits phosphodiesterase type 6 (PDE6), an essential enzyme involved in the activation and modulation of the phototransduction cascade. Although Viagra might thus be expected to impair visual performance, reports of deficits following its ingestion have so far been largely inconclusive or anecdotal. Here, we adopt tests sensitive to the slowing of the visual response likely to result from the inhibition of PDE6. We measured temporal acuity (critical fusion frequency) and modulation sensitivity in four subjects before and after the ingestion of a 100-mg dose of Viagra under conditions chosen to isolate the responses of either their short-wavelength-sensitive (S-) cone photoreceptors or their long- and middle-wavelength-sensitive (L- and M-) cones. When vision was mediated by S-cones, all subjects exhibited some statistically significant losses in sensitivity, which varied from mild to moderate. The two individuals who showed the largest S-cone sensitivity losses also showed comparable losses when their vision was mediated by the L- and M-cones. Some of the losses appear to increase with frequency, which is broadly consistent with Viagra interfering with the ability of PDE6 to shorten the time over which the visual system integrates signals as the light level increases. However, others appear to represent a roughly frequency-independent attenuation of the visual signal, which might also be consistent with Viagra lengthening the integration time (because it has the effect of increasing the effectiveness of steady background lights), but such changes are also open to other interpretations. Even for the more affected observers, however, Viagra is unlikely to impair common visual tasks, except under conditions of reduced visibility when objects are already near visual threshold.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17685811     DOI: 10.1167/7.8.4

Source DB:  PubMed          Journal:  J Vis        ISSN: 1534-7362            Impact factor:   2.240


  11 in total

1.  Increased bioavailability of cyclic guanylate monophosphate prevents retinal ganglion cell degeneration.

Authors:  Lauren K Wareham; Ana C Dordea; Grigorij Schleifer; Vincent Yao; Annabelle Batten; Fei Fei; Joseph Mertz; Meredith Gregory-Ksander; Louis R Pasquale; Emmanuel S Buys; Rebecca M Sappington
Journal:  Neurobiol Dis       Date:  2018-09-10       Impact factor: 5.996

2.  Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit.

Authors:  Brandy Barren; Lokesh Gakhar; Hakim Muradov; Kimberly K Boyd; S Ramaswamy; Nikolai O Artemyev
Journal:  EMBO J       Date:  2009-10-01       Impact factor: 11.598

3.  X-linked cone dystrophy caused by mutation of the red and green cone opsins.

Authors:  Jessica C Gardner; Tom R Webb; Naheed Kanuga; Anthony G Robson; Graham E Holder; Andrew Stockman; Caterina Ripamonti; Neil D Ebenezer; Olufunmilola Ogun; Sophie Devery; Genevieve A Wright; Eamonn R Maher; Michael E Cheetham; Anthony T Moore; Michel Michaelides; Alison J Hardcastle
Journal:  Am J Hum Genet       Date:  2010-06-24       Impact factor: 11.025

4.  A detailed phenotypic description of autosomal dominant cone dystrophy due to a de novo mutation in the GUCY2D gene.

Authors:  R Mukherjee; A G Robson; G E Holder; A Stockman; C A Egan; A T Moore; A R Webster
Journal:  Eye (Lond)       Date:  2014-01-31       Impact factor: 3.775

5.  Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis.

Authors:  Sevdalina Nikolova; Andreas Guenther; Rajkumar Savai; Norbert Weissmann; Hossein A Ghofrani; Melanie Konigshoff; Oliver Eickelberg; Walter Klepetko; Robert Voswinckel; Werner Seeger; Friedrich Grimminger; Ralph T Schermuly; Soni S Pullamsetti
Journal:  Respir Res       Date:  2010-10-27

6.  A novel mutation and phenotypes in phosphodiesterase 6 deficiency.

Authors:  Stephen H Tsang; Irena Tsui; Chai Lin Chou; Jana Zernant; Eneli Haamer; Reza Iranmanesh; Joaquin Tosi; Rando Allikmets
Journal:  Am J Ophthalmol       Date:  2008-08-23       Impact factor: 5.258

Review 7.  Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review.

Authors:  Francisco Barroso; João Crispim Ribeiro; Eduardo P Miranda
Journal:  J Ophthalmic Vis Res       Date:  2021-04-29

8.  cGMP-phosphodiesterase inhibition enhances photic responses and synchronization of the biological circadian clock in rodents.

Authors:  Santiago A Plano; Patricia V Agostino; Horacio O de la Iglesia; Diego A Golombek
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

Review 9.  Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction.

Authors:  Marilita M Moschos; Eirini Nitoda
Journal:  Drug Des Devel Ther       Date:  2016-10-19       Impact factor: 4.162

10.  Changes in Retinal and Choroidal Vascular Blood Flow after Oral Sildenafil: An Optical Coherence Tomography Angiography Study.

Authors:  David Berrones; Guillermo Salcedo-Villanueva; Virgilio Morales-Cantón; Raul Velez-Montoya
Journal:  J Ophthalmol       Date:  2017-10-09       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.